| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71c2dd47a2ebe67f392e582393e8b29d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2017-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b91bb8dc31b06828b5cba9ce83145948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2caa042a721fb2e3bcc4470b091c742b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a5a6cd39383d3147a404714e5e7cd0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_879e64170c8b75cafd6ec2c2cdb2533f |
| publicationDate |
2018-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018017673-A1 |
| titleOfInvention |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| abstract |
Anti-cancer treatment and therapeutic methods are provided in which an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 and blocks binding of PD-L1 to PD-1 is administered to a subject in need in combination with an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, blocks binding of PD-L1 to PD-1 and also promotes internalization and degradation of PD-L1. The anti-cancer methods utilize antibodies that recognize specific epitopes on glycosylated PD-L1 protein, as well as antibodies that exhibit the IPD function of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells expressing PD-L1. Methods in which such antibody combinations are especially useful include cancer and tumor treatments and therapies in which the cancer or tumor is a PD-L1 positive cancer or tumor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021150701-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021150702-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3802577-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020011973-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214620-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11548948-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11629193-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214618-B2 |
| priorityDate |
2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |